Skip to main content

Table 5 Background characteristics on patients harboring the T790M substitution upon rebiopsy (n = 89)

From: Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

Variable T790M mutation  
Positive
(n = 35)
Negative
(n = 54)
Total
Original mutation
 Absent 3 40 43
 Present 32 14 46
Type of Biopsy;
 Liquid 11 47 58
 Tissue 24 7 31
Detection of New tumor lesion;
  <  4 11 39 50
 4 ≤ 24 15 39
Number of Tissue biopsy
 Median (Range) 1 (0–4) 0 (0–3) 0 (0–4)
Detection of New metastatic organ, n = 88
 0 12 39 51
 1 12 10 22
 2 4 4 8
 3 3 1 4
 4 3 0 3
Number of tumor lesion
  <  6 6 29 35
 6 ≤ 29 25 54
Brain metastases, n = 88
 Absent 16 43 59
 Present 18 11 29
Bone metastases, n = 88
 Absent 26 42 68
 Present 8 12 20
Number of Liquid biopsy
 Median (Range) 0 (0–8) 2 (0–9) 1 (0–9)
Enlargement of Tumor size
  <  12 mm 15 39 54
 12 mm ≤ 20 15 35
New brain metastases, n = 88
 Absent 25 50 75
 Present 9 4 13
Mutation site at initial diagnosis
 Exon19 Deletion 24 47 71
 L858R 11 7 18
Minor site metastases, n = 88
 Absent 27 51 78
 Present 7 3 10
New hepatic metastases, n = 88
 Absent 28 51 79
 Present 6 3 9
New minor site metastases, n = 88
 Absent 29 52 81
 Present 5 2 7
Hepatic metastases, n = 88
 Absent 27 49 76
 Present 7 5 12
  1. Abbreviations: n; number, minor site metastases; metastases of skin, kidney, ascites, lymphangiosis carcinomatosa, adrenal organ or others,